PharmiWeb.com - Global Pharma News & Resources
02-Sep-2024

Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights

Marinomed Biotech AG / Key word(s): Corporate Action
Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights

02-Sep-2024 / 17:46 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Korneuburg, Austria, 02. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board decided today to evaluate a capital increase of up to 154,053 new shares to be issued from the Authorized Capital 2024, subject to the direct exclusion of statutory subscription rights of existing shareholders, to finance the ongoing costs in the restructuring proceedings, to finance part of the restructuring plan proposal and for costs of continuing operations. This corresponds to up to 10% of the Company's existing share capital.

For the purpose of the evaluation, the Management Board will enter into discussions with selected investors regarding the potential transaction and the transaction documentation. The actual implementation of the capital increase depends on the outcome of these discussions and is subject to further resolution by the Management Board and approval of the Supervisory Board. In addition, the restructuring proceedings require the approval of the restructuring administrator. These approvals have not yet been obtained.

If the capital increase is implemented, the Management Board is considering a possible second capital increase of 10% of the Company's existing share capital, with exclusion of the statutory subscription rights of existing shareholders.

+++ End of ad-hoc announcement +++ 
 

End of Inside Information

02-Sep-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com


Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID: 1979933

 
End of Announcement EQS News Service

Editor Details

Last Updated: 02-Sep-2024